-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Current studies have shown that rituximab (RTX) is effective for active Graves' ophthalmopathy (GO)
Rituximab (RTX) is effective for active Graves ophthalmopathy (GO)
Methods: To compare the effects of RTX and intravenous methylprednisolone (ivMP) in the treatment of patients with active moderate to severe Graves ophthalmopathy (GO)
Methods: To compare the effects of RTX and intravenous methylprednisolone (ivMP) in the treatment of patients with active moderate to severe Graves ophthalmopathy (GO)
Results: The clinical activity scores of the two groups of patients decreased, but decreased more after 16 weeks, 20 weeks and 24 weeks of RTX (P<0.
Figure 2 Changes in serum TRAbs activity of GO patients after intravenous injection of MP or RTX from baseline to 76-week follow-up
Conclusion: The results of this trial confirmed the preliminary report that compared with ivMP, even with lower doses of RTX, RTX is more effective in the treatment of active moderate to severe GO
The results of this trial confirmed the preliminary report that, compared with ivMP, even with lower doses of RTX, RTX is more effective in the treatment of active moderate to severe GO
Original source:
Salvi M, Vannucchi G, Currò N, et al, Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study .
Salvi M, Vannucchi G, Currò N, et al, Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study .
Efficacy of B-cell targeted therapy with rituximab in patients with active Graves 'to Severe.
Moderate' orbitopathy: A randomized Controlled Study J Clin Endocrinol Metab, 2015 on Feb; 100 (2)
in this message